Aclaris Therapeutics, Inc. (ACRS) Key Metrics
ACRS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $482.8M
- Enterprise value
- $682.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 58.7 10-yr median 29.3
- Price / book
- 6.2 10-yr median 2.4
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 0.88
ACRS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACRS valuation Price multiples at each fiscal year-end price.
ACRS returns How much profit the business earns on the capital it uses.
ACRS per-share figures Results divided by the shares outstanding at year-end.
ACRS financial health Debt, liquidity and how easily interest is covered.
ACRS efficiency & capital use Working capital cycle and where the cash goes.
ACRS valuation history
ACRS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACRS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACRS cash returned to shareholders
ACRS price vs earnings per share
ACRS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $369.2M | $191.7M | $73.3M | $1.03B | $824.9M | $275.2M | $78.1M | $243.2M | — | — |
| Enterprise value | $280.6M | $80.7M | −$45.4M | $810.2M | $634.1M | $232.4M | $3.7M | $105.7M | — | — |
| Price / sales | 47.2 | 10.2 | 2.3 | 34.5 | 122.0 | 42.5 | 18.5 | 24.1 | — | — |
| Price / book | 3.6 | 1.2 | 0.5 | 5.2 | 4.2 | 7.3 | 1.1 | 1.1 | — | — |
| EV / sales | 35.9 | 4.3 | -1.5 | 27.2 | 93.8 | 35.8 | 0.9 | 10.5 | — | — |
| Earnings yield | −17.6% | −68.9% | −120.7% | −8.5% | −11.0% | −18.6% | −206.6% | −54.6% | — | — |
| Free cash flow yield | −12.8% | −10.5% | −108.6% | −6.6% | −6.4% | −14.2% | −125.6% | −42.0% | — | — |
| Dividend yield | — | — | — | — | 0.4% | 2.8% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.1% | — | 0.1% | 0.0% | 0.8% | 2.8% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $3.01 | $2.48 | $1.05 | $15.75 | $14.54 | $6.47 | $1.89 | $7.39 | $24.66 | $27.14 |
| Per share | ||||||||||
| Revenue per share | $0.06 | $0.24 | $0.45 | $0.46 | $0.12 | $0.15 | $0.10 | $0.31 | — | — |
| Earnings per share | −$0.53 | −$1.71 | −$1.27 | −$1.33 | −$1.60 | −$1.20 | −$3.90 | −$4.03 | — | — |
| Operating cash flow per share | −$0.38 | −$0.26 | −$1.12 | −$1.04 | −$0.92 | −$0.91 | −$2.33 | −$3.06 | — | — |
| Free cash flow per share | −$0.38 | −$0.26 | −$1.14 | −$1.05 | −$0.92 | −$0.92 | −$2.37 | −$3.10 | — | — |
| Cash per share | $0.74 | $1.47 | $1.71 | $3.34 | $3.37 | $1.27 | $1.82 | $5.10 | — | — |
| Book value per share | $0.84 | $2.01 | $2.25 | $3.03 | $3.48 | $0.89 | $1.69 | $6.54 | — | — |
| Tangible book value per share | $0.84 | $2.01 | $2.25 | $2.92 | $3.35 | $0.72 | $1.52 | $3.76 | — | — |
| Dividends per share | — | — | — | — | $0.06 | $0.18 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.02 | $0.01 | $0.01 | $0.01 | $0.04 | $0.04 | — | — |
| Debt per share | $0.02 | $0.03 | $0.01 | $0.01 | $0.01 | $0.26 | $0.02 | $0.93 | — | — |
| Shares outstanding | 122.7M | 77.3M | 69.8M | 65.2M | 56.7M | 42.5M | 41.3M | 32.9M | — | — |
| Change in shares outstanding | +58.7% | +10.7% | +7.0% | +15.0% | +33.4% | +2.9% | +25.6% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −50.2% | −84.5% | −49.9% | −44.0% | −77.3% | −95.1% | −113.2% | −60.3% | −34.7% | −36.7% |
| Return on invested capital (ROIC) | −204.5% | −270.0% | −799.8% | — | — | — | — | −227.1% | −961.1% | — |
| Return on assets (ROA) | −34.1% | −63.2% | −39.2% | −34.4% | −56.4% | −60.5% | −86.3% | −51.1% | −32.7% | −35.6% |
| Return on tangible assets | −40.5% | −59.9% | −44.9% | −35.1% | −37.2% | −80.4% | −177.1% | −72.1% | −31.5% | −27.3% |
| Free cash flow margin | −602.0% | −107.9% | −254.8% | −229.1% | −775.7% | −603.0% | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.1M | $2.6M | $426,000 | $684,000 | $693,000 | $11.3M | $658,000 | $30.5M | $142,000 | $0 |
| Cash & short-term investments | $90.8M | $113.6M | $119.1M | $217.6M | $191.4M | $54.1M | $75.0M | $168.0M | $208.9M | $174.1M |
| Net debt | −$88.6M | −$111.0M | −$118.7M | −$216.9M | −$190.7M | −$42.9M | −$74.4M | −$137.5M | −$208.7M | −$174.1M |
| Debt / equity | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.30 | 0.01 | 0.14 | 0.00 | 0.00 |
| Debt / assets | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.16 | 0.01 | 0.11 | 0.00 | 0.00 |
| Current ratio | 5.28 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.56 | 16.37 | 27.98 |
| Quick ratio | 5.28 | 3.99 | 4.16 | 11.11 | 10.43 | 3.87 | 3.51 | 6.54 | 16.86 | 27.98 |
| Interest coverage | — | — | — | -19.1 | -3.8 | -49.0 | — | — | — | — |
| Working capital | $122.7M | $94.4M | $97.9M | $209.6M | $182.1M | $42.6M | $61.4M | $152.2M | $196.1M | $167.9M |
| Invested capital | $14.4M | $44.6M | $38.5M | −$19.3M | $6.6M | −$5.2M | −$4.4M | $77.7M | $16.6M | −$4.6M |
| Tangible asset value | $103.1M | $155.6M | $156.9M | $190.6M | $190.3M | $30.5M | $62.7M | $123.7M | $199.4M | $169.5M |
| Net current asset value | $94.0M | $61.2M | $88.6M | $174.6M | $151.2M | $24.4M | $55.4M | $119.1M | $190.6M | $167.5M |
| Graham net-net per share | $0.31 | $0.63 | $1.13 | $2.37 | $2.13 | $0.51 | $1.20 | $3.29 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $3.1M | $7.7M | — | — | $0 | $0 |
| Share buybacks (net) | $446,000 | — | $102,000 | $34,000 | $3.1M | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 1.4% | 0.6% | 4.2% | 2.0% | 4.6% | 7.0% | 38.2% | 13.4% | 73.4% | — |
| Capex / depreciation | 0.24 | 0.15 | 1.52 | 0.76 | 0.33 | 0.34 | 1.02 | 1.02 | 3.07 | 1.93 |
| Stock-based compensation / revenue | 158.2% | 58.0% | 65.7% | 50.5% | 208.0% | 172.9% | 382.7% | 198.7% | 857.4% | — |
| R&D / revenue | 672.7% | 179.4% | 314.8% | 261.5% | 648.0% | 489.5% | 1,535.3% | 624.4% | 2,364.2% | — |
| SG&A / revenue | 280.8% | 118.6% | 99.5% | 84.5% | 349.3% | 321.1% | 658.3% | 749.6% | 1,972.3% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 137.2 | 6.0 | 4.6 | 6.8 | 37.7 | 41.6 | 54.7 | 18.9 | 104.3 | — |
| Days of inventory on hand | — | — | — | -709.3 | -2,651.9 | — | 259.1 | -148.5 | -962.2 | — |
| Days payables outstanding | 1,557.8 | 886.9 | 194.1 | 310.3 | 590.1 | 539.4 | 971.8 | 519.4 | 1,612.9 | 5,558.6 |
| Cash conversion cycle (days) | -1,420.6 | -880.9 | -189.5 | -1,012.8 | -3,204.3 | -497.8 | -658.0 | -649.0 | -2,470.8 | — |
| Receivables turnover | 2.66 | 60.78 | 79.92 | 53.75 | 9.69 | 8.78 | 6.67 | 19.33 | 3.50 | — |
| Payables turnover | 0.23 | 0.41 | 1.88 | 1.18 | 0.62 | 0.68 | 0.38 | 0.70 | 0.23 | 0.07 |
| Inventory turnover | — | — | — | — | — | — | 1.41 | — | — | — |
| Asset turnover | 0.04 | 0.09 | 0.14 | 0.12 | 0.04 | 0.08 | 0.02 | 0.04 | 0.01 | 0.00 |
| Average receivables | $2.9M | $308,000 | $391,000 | $553,500 | $697,500 | $738,000 | $633,500 | $522,000 | $481,000 | — |
| Average payables | $8.9M | $6.8M | $9.6M | $10.2M | $7.6M | $7.6M | $10.8M | $9.7M | $5.3M | $1.8M |
| Average inventory | — | — | — | −$23.2M | −$34.2M | — | $2.9M | −$2.8M | −$3.2M | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.1% | 2.7% | 2.8% | 10.1% | 7.3% | 33.2% | 10.6% | 0.0% |
Computed from ACRS's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACRS valuation and financial ratios
Aclaris Therapeutics earned a return on equity of −50.2% and a return on invested capital of −204.5% in fiscal 2025. It ended the year with $2.1 million of debt and $90.8 million in cash and short-term investments, a net cash position of $88.6 million. It returned $0.4 million to shareholders: $0 in dividends and $0.4 million in share buybacks.
See the ACRS income statement, the ACRS chart for price history, or the ACRS stock overview for the latest quote and news.
ACRS key metrics FAQ
What is Aclaris Therapeutics's return on equity?
Aclaris Therapeutics's return on equity (ROE) was −50.2% in fiscal 2025: net income of -$64.9 million on average shareholders' equity of $129.3 million.
What is Aclaris Therapeutics's ROIC?
Aclaris Therapeutics's return on invested capital was −204.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Aclaris Therapeutics have?
Aclaris Therapeutics had total debt of $2.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
Does Aclaris Therapeutics buy back its shares?
Yes. Aclaris Therapeutics spent $0.4 million on net share repurchases in fiscal 2025 Shares outstanding changed +58.7% over the year, to 122.7M..
What is Aclaris Therapeutics's free cash flow yield?
Aclaris Therapeutics generated -$47.1 million of free cash flow in fiscal 2025, a free cash flow yield of −12.8% on its market value at year-end ($369.2 million).
What is Aclaris Therapeutics's current ratio?
Aclaris Therapeutics's current ratio was 5.28 at the end of fiscal 2025: current assets were 5.28 times current liabilities.